Pay in 4 interest-free payments of $5.99 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Is GHK-Cu safe for pre-clinical research
Tissue Regeneration: Stimulates the regeneration of muscle, tendon, and other tissues, aiding in wound healing
Reduces appetite aids weight loss Common Drugs (Examples) Exenatide Liraglutide Dulaglutide Semaglutide Lixisenatide Clinical Uses Type 2 Diabetes Mellitus (as monotherapy or combination) Obesity / weight management (especially semaglutide, liraglutide) Cardiovascular benefit: reduces major adverse CV events in T2DM with CVD Administration Subcutaneous injection (daily or weekly depending on formulation) Oral semaglutide available for some patients Adverse Effects Gastrointestinal: nausea, vomiting, diarrhea Risk of pancreatitis (rare but serious) Mild hypoglycemia if combined with sulfonylureas or insulin Injection site reactions Contraindications / Precautions Personal/family history of medullary thyroid carcinoma History of multiple endocrine neoplasia syndrome type 2 (MEN2) Severe gastrointestinal disease (gastroparesis) GLP-1 agonists = incretin mimetics
General dosage considerations: CJC-1295 + Ipamorelin: Often dosed nightly AOD-9604: Daily or alternate-day dosing GLP-1 mimetics: Weekly dosing MOTS-C: Cyclic injection schedules (e.g., 23/week) Treatment Duration: Typical fat-loss cycles span 816 weeks with maintenance protocols afterward
